Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook
Q32 Bio shares jumped as much as 170% intraday on December 1 after announcing the sale of its Phase 2 drug ADX-097 to Akebia Therapeutics for $12 million upfront and up to $592 million in milestones. Trading volume soared into the hundreds of millions. The company will now focus on its lead autoimmune drug, bempikibart, for alopecia areata.
